Prostate Cancer Research

This page contains a list of citations for selected publications about prostate cancer authored by CDC's Division of Cancer Prevention and Control (DCPC) staff members. Fiscal years begin October 1 and end September 30; for example, fiscal year 2009 began October 1, 2008 and ends September 30, 2009.

Fiscal Year 2009

Ross LE, Taylor YJ, Richardson LC, Howard DL. Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002–2006. Journal of the National Medical Association 2009;101(4):316–324.

Fiscal Year 2008

Berge V, Thompson T, Blackman D. Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting. European Urology 2007;52(4):1036–1043.

Coates RJ, Khoury MJ, Gwinn M. Five genetic variants associated with prostate cancer. New England Journal of Medicine 2008;358(25):2738.

Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Preventing Chronic Disease 2007;4(4):A100.

Henderson JA, Espey DK, Jim MA, German RR, Shaw KM, Hoffman RM. Prostate cancer incidence among American Indian and Alaska Native men, US, 1999–2004. Cancer 2008;113(S5):1203–1212.

Richert-Boe KE, Weinmann S, Shapiro JA, Rybicki BA, Enger SM, Van Den Eeden SK, Weiss NS. Racial differences in treatment of early-stage prostate cancer. Urology 2008;71(6):1172–1176.

Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men: Findings from the 2005 National Health Interview Survey. Cancer Epidemiology, Biomarkers and Prevention 2008;17(3):636–644.

Volk RJ, Hawley ST, Kneuper S, Holden EW, Stroud LA, Cooper CP, Berkowitz JM, Scholl LE, Saraykar SS, Pavlik VN. Trials of decision aids for prostate cancer screening: A systematic review. American Journal of Preventive Medicine 2007;33(5):428–434.

Werny DM, Saraiya M, Carrera J, Coughlin SS, Frank E. Learning amid controversy: prostate cancer knowledge and screening practices among US medical students. Journal of Cancer Education 2008;23(2):108–113.

Werny DM, Saraiya M, Platz EA, Chen X. Prostate-specific antigen, sexual behavior, and sexually transmitted infections in US men 40–59 years old, 2001–2004: a cross-sectional study. Infectious Agents and Cancer 2007;2(1):19.

Fiscal Year 2007

Berge V, Thompson T, Blackman D. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting. Scandinavian Journal of Urology and Nephrology 2007;41(3):198–203.

Hughes E, McCracken M, Roberts H, Mokdad AH, Valluru B, Goodson R, Dunn E, Elam-Evans L, Giles W, Jiles R. Surveillance for certain health behaviors among states and selected local areas—Behavioral Risk Factor Surveillance System, United States, 2004. MMWR Surveillance Summaries 2006;55(7):1–124.

Lacher DA, Thompson TD, Hughes JP, Saraiya M. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001–04. (PDF) Advance Data from Vital and Health Statistics no. 379. Hyattsville, MD: National Center for Health Statistics, 2006.

Marcella S, Delnevo CD, Coughlin SS. A national survey of medical students’ beliefs and knowledge in screening for prostate cancer. Journal of General Internal Medicine 2007;22(1):80–85.

QuickStats: Percentage of Men Aged ≥ 40 Years* with Prostate-Specific Antigen (PSA) Levels of ≥ 2.5 and ≥ 4.0 ng/mL, by Race/Ethnicity—National Health and Nutrition Examination Survey, United States, 2001–2004. MMWR 2006;55(48);1305.

Ramsey SD, Zeliadt SB, Hall IJ, Ekwueme DU, Penson DF. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. Journal of Urology 2007;177(6):1992–1999.

Ross LE, Richardson LC, Berkowitz Z. The effect of physician-patient discussions on the likelihood of prostate-specific antigen testing. Journal of the National Medical Association 2006;98(11):1823–1829.

Stroud L, Ross LE, Rose SW. Formative evaluation of the prostate cancer screening practices of African-American physicians. Journal of the National Medical Association 2006;98(10):1637–1643.

Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001–2002. American Journal of Epidemiology 2006;164(10):978–983.

Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, Wener M. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001–2004. Cancer Epidemiology, Biomarkers and Prevention 2007;16(1):70–76.

Fiscal Year 2006

German RR, Thompson TD, Stewart SL, Wingo PA, Ledford K. Distribution of male genital system cancers (MGSC), United States—1998–2002. American Journal of Epidemiology 2006;163(11):S92.

Ross LE, Stroud LA, Rose SW, Jorgensen CM. Using telephone focus groups methodology to examine the prostate cancer screening practices of African-American primary care physicians. Journal of the National Medical Association 2006;98(8):1296–1299.

Ross LE, Uhler RJ. Age, race, and repeated prostate-specific antigen (PSA) test use in the National Health Interview Survey. Ethnicity and Disease 2006;16(1):244–247.

Tannor BB, Ross L. Physician-patient discussions about prostate-specific antigen test use among African-American men. Journal of the National Medical Association 2006;98(4):532–538.

Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 2006;106(9):1865–1874.

Fiscal Year 2005

German RR, Thompson TD, Stewart SL, Friedman C, Wingo P. Geographic patterns of prostate cancer incidence and mortality—United States, 2001. Journal of Clinical Oncology 2005;23(16S):415s.

Hoffman RM, Stone SN, Espey D, Potosky AL. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer 2005;5(1):27.

Ross LE, Uhler RJ, Williams KN. Awareness and use of the prostate-specific antigen test among African-American men. Journal of the National Medical Association 2005;97(7):963–971.

Saraiya M, Kottiri BJ, Leadbetter S, Blackman D, Thompson T, McKenna MT, Stallings FL. Total and percent free prostate-specific antigen levels among U.S. men, 2001–2002. Cancer Epidemiology, Biomarkers and Prevention 2005;14(9):1–5.

Weinmann S, Richert-Boe KE, Van Den Eeden SK, Enger SM, Rybicki BA, Shapiro JA, Weiss NS. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: A case-control study. Epidemiology 2005; 16(3):367–376. (An erratum appears in Epidemiology 2005;16(4):515 due to several publisher errors in Table 5).

Fiscal Year 2004

Briss P, Rimer B, Reilley B, Coates RJ, Lee NC, Mullen P, Corso P, Hutchinson AB, Hiatt R, Kerner J, George P, White C, Gandhi N, Saraiya M, Breslow R, Isham G, Teutsch SM, Hinman AR, Lawrence R. Promoting informed decisions about cancer screening in communities and healthcare systems. American Journal of Preventive Medicine 2004;26(1):67–80.

Cooper CP, Merritt TL, Ross LE, John LV, Jorgensen CM. To screen or not to screen, when clinical guidelines disagree: Primary care physicians' use of the PSA test. Preventive Medicine 2004;38(2):182–191.

Hall HI, Van Den Eeden SK, Tolsma DD, Rardin K, Thompson T, Hughes SA, Madlon-Kay DJ, Nadel M. Testing for prostate and colorectal cancer: Comparison of self-report and medical record audit. Preventive Medicine 2004;39(1):27–35.

Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Preventive Medicine 2004;38(6):732–744.

Tseng M, Breslow RA, DeVellis RF, Ziegler RG. Dietary patterns and prostate cancer risk in the National Health and Nutrition Examination Survey Epidemiological Follow-up Study Cohort. Cancer Epidemiology, Biomarkers and Prevention 2004;13(1):71–77.

Fiscal Year 2003

Cooper CP, Jorgensen CM, Green CL, Ross LE. CDC's decision aid for prostate cancer screening. Health Education and Behavior 2003;30:534–536.

Fleming ST, Pearce KA, McDavid K, Pavlov D. The development and validation of a comorbidity index for prostate cancer among black men. American Journal of Clinical Epidemiology 2003;56(11):1064–1075.

Fiscal Year 2002

Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Annals of Epidemiology 2002;12(3):182–196.

Gargiullo P, Wingo PA, Coates RJ, Thompson TD. Recent trends in mortality rates for four major cancers, by sex and race/ethnicity—United States, 1990–1998. MMWR 2002;51(3):49–53.

Fiscal Year 2000

Hawk E, Breslow R, Graubard B. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiology, Biomarkers and Prevention 2000;9(5):523–527.

McDavid K, Melnik T, Derderian H. Prostate cancer screening trends of New York state men at least 50 years old, 1994 to 1997. Preventive Medicine 2000;31(3):195–202.

Steele CB, Miller DS, Maylahn C, Uhler RJ, Baker CT. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. American Journal of Public Health 2000;90(10):1595–1600.